EyePoint (EYPT) Pharmaceuticals announced that it has commenced an underwritten public offering of $100M of shares of its common stock. J.P. Morgan, Citigroup and Guggenheim Securities are acting as joint book running managers for the offering.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EYPT:
- EyePoint announces interim 16-week data for ongoing Phase 2 VERONA trial
- EYPT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- EyePoint announces first patient dosed in global Phase 3 LUGANO trial
- ANI Pharmaceuticals price target raised to $62 from $60 at Truist
- Biotech Alert: Searches spiking for these stocks today